Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas
Company profile
Ticker
ARNA
Exchange
Website
CEO
Amit Munshi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
125 Royalty Inc. • 356 Royalty Inc. • Arena Pharmaceuticals Canada Holdings, LP • Arena Pharmaceuticals Development GmbH, a limited liability company • Arena Pharmaceuticals Development, LLC • Arena Pharmaceuticals GmbH • Arena Pharmaceuticals Holdings, Inc. • Arena Pharmaceuticals Limited, a limited liability company • Arena Pharmaceuticals, LLC • Arena Pharmaceuticals Netherlands BV ...
IRS number
232908305
ARNA stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Mar 22
EFFECT
Notice of effectiveness
16 Mar 22
EFFECT
Notice of effectiveness
16 Mar 22
EFFECT
Notice of effectiveness
16 Mar 22
EFFECT
Notice of effectiveness
16 Mar 22
25-NSE
Exchange delisting
11 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
11 Mar 22
POS AM
Prospectus update (post-effective amendment)
11 Mar 22
POS AM
Prospectus update (post-effective amendment)
11 Mar 22
POS AM
Prospectus update (post-effective amendment)
11 Mar 22
Transcripts
ARNA
Earnings call transcript
2021 Q3
5 Nov 21
ARNA
Earnings call transcript
2021 Q2
6 Aug 21
ARNA
Earnings call transcript
2021 Q1
6 May 21
ARNA
Earnings call transcript
2020 Q4
24 Feb 21
ARNA
Earnings call transcript
2020 Q3
9 Nov 20
ARNA
Earnings call transcript
2020 Q2
6 Aug 20
ARNA
Earnings call transcript
2020 Q1
7 May 20
ARNA
Earnings call transcript
2019 Q4
27 Feb 20
ARNA
Earnings call transcript
2019 Q3
7 Nov 19
ARNA
Earnings call transcript
2019 Q2
8 Aug 19
Latest ownership filings
4
Longboard Pharmaceuticals, Inc.
29 Jan 24
4
Tina Susan Nova
11 Mar 22
4
OLIVER FETZER
11 Mar 22
4
KIERAN GALLAHUE
11 Mar 22
4
Katharine Knobil
11 Mar 22
4
Jennifer Jarrett
11 Mar 22
4
GARRY ARTHUR NEIL
11 Mar 22
4
Steven J Schoch
11 Mar 22
4
Jayson Donald Alexander Dallas
11 Mar 22
4
Nawal Ouzren
11 Mar 22
Financial summary
Quarter (USD) | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 224.80 mm | 224.80 mm | 224.80 mm | 224.80 mm | 224.80 mm | 224.80 mm |
Cash burn (monthly) | 54.03 mm | (no burn) | 51.14 mm | 52.02 mm | 40.17 mm | 37.67 mm |
Cash used (since last report) | 1.50 bn | n/a | 1.42 bn | 1.44 bn | 1.12 bn | 1.05 bn |
Cash remaining | -1.28 bn | n/a | -1.20 bn | -1.22 bn | -890.75 mm | -821.39 mm |
Runway (months of cash) | -23.6 | n/a | -23.4 | -23.5 | -22.2 | -21.8 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Jan 24 | Arena Pharmaceuticals | Voting Common Stock | Sell | Dispose S | No | No | 24.25 | 3,978,540 | 96.48 mm | 0 |